1. Scrip
  2. >>R&D

Strongbridge Makes Case For Recorlev In First-Line Cushing's Disease

 
• By Emily Hayes

Recorlev (levoketoconazole) demonstrates efficacy and liver safety in a Phase III single-arm study, but needs to live down the bad rap of ketoconazole and ultimately escape a black box warning.

Human kidney cross section on scientific background showing adrenal gland as well. 3d illustration

Strongbridge Biopharma PLC believes the robust efficacy and safety – particularly in the liver – of its Recorlev (levoketoconazole) support a first-line role in Cushing's syndrome, a rare endocrinologic condition marked by excess cortisol.

Strongbridge (formerly called Cortendo) announced positive results from the Phase III pivotal SONICS study of Recorlev for endogenous Cushing's syndrome on Aug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.